Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) EBITDA Margin (2020 - 2022)

Candel Therapeutics' EBITDA Margin history spans 3 years, with the latest figure at 26132.26% for Q4 2022.

  • On a quarterly basis, EBITDA Margin fell 5273226.0% to 26132.26% in Q4 2022 year-over-year; TTM through Dec 2022 was 28000.81%, a 866889.0% increase, with the full-year FY2022 number at 27777.6%, up 834640.0% from a year prior.
  • EBITDA Margin hit 26132.26% in Q4 2022 for Candel Therapeutics, up from 28648.39% in the prior quarter.
  • Over the last five years, EBITDA Margin for CADL hit a ceiling of 26600.0% in Q4 2021 and a floor of 55096.77% in Q2 2021.
  • Historically, EBITDA Margin has averaged 23468.91% across 3 years, with a median of 28235.48% in 2022.
  • Biggest five-year swings in EBITDA Margin: soared 6056129bps in 2021 and later plummeted -5273226bps in 2022.
  • Tracing CADL's EBITDA Margin over 3 years: stood at 33961.29% in 2020, then surged by 178bps to 26600.0% in 2021, then plummeted by -198bps to 26132.26% in 2022.
  • Business Quant data shows EBITDA Margin for CADL at 26132.26% in Q4 2022, 28648.39% in Q3 2022, and 28235.48% in Q2 2022.